Two fully enrolled Phase 3 trials plus an oral formulation in Phase 3 pipeline — thesis turns on whether VANQUISH efficacy data can carve share from Wegovy and Zepbound

Bull

A positive outcome would show that subjects who achieved weight loss on VK2735 can maintain that loss on less-frequent dosing schedules — particularly monthly subcutaneous or weekly oral regimens — demonstrating superior convenience relative to Wegovy and Zepbound without sacrificing durability. This would meaningfully de-risk the commercial differentiation story ahead of VANQUISH efficacy data and validate the broader platform flexibility, potentially reinforcing investor confidence in the oral Phase 3 program as well.

Bear

The primary failure mode is meaningful weight regain after dose reduction or spacing, which would signal that VK2735 requires continuous high-frequency dosing to sustain efficacy — eliminating a key hypothesized advantage over approved competitors. A secondary risk is that tolerability issues emerge with alternative dosing regimens, narrowing the addressable dosing window and complicating the label strategy the company may be pursuing.